CCL2 and diabetes mellitus: Fenofibrate shows favorable effects in reducing the cytokine-provoked release of TNF-α, IL-1, IL-6, monocyte chemoattractant protein 1 (MCP-1), and plasma hs-CRP from monocytes in patients with pre-diabetes [39, 40].